Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Low-dose IL-12 preconditions the tumor microenvironment to enhance the efficacy of PD-1 blockade.
Authors
C. Marcela Diaz-Montero
Cleveland Clinic Lerner Research Institute, Cleveland, OH
C. Marcela Diaz-Montero, Sairekha Ravichandran, Paul G. Pavicic, Patricia A. Rayman, Charles Tannenbaum, James Finke, Jennifer S. Ko, Pauline Funchain, Ahmad A. Tarhini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Novel Clinical Trial Designs
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr 20)
DOI
10.1200/JCO.2019.37.8_suppl.20
Abstract #
20
Poster Bd #
B4
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
High CXCR4 expression in pancreatic ductal adenocarcinoma as characterized by an inflammatory tumor phenotype with potential implications for an immunotherapeutic approach.
First Author: Andreas Seeber
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Distinct dominant T-cell receptors with a tissue resident memory phenotype in individual melanoma metastases.
First Author: Kavita M. Dhodapkar
Poster
2015 ASCO Annual Meeting
Anti-tumor efficacy and PD-L1 expression in the tumor microenvironment after poxvirus-based active immunotherapy and PD-1 blockade.
First Author: Stefanie J Mandl
Poster
2024 ASCO Annual Meeting
A first-in-human phase 1 trial of T cell membrane-anchored tumor targeted IL12 (ATTIL12) -T cell therapy in advanced/metastatic soft tissue and bone sarcoma.
First Author: J. Andrew Livingston